Daniel E. Geffken
2022 - Sevion Therapeutics
In 2022, Daniel E. Geffken earned a total compensation of $64K as Interim Chief Financial Officer at Sevion Therapeutics, a 51% decrease compared to previous year.
Compensation breakdown
| Other | $63,960 |
|---|---|
| Total | $63,960 |
Geffken received $64K in other compensation, accounting for 100% of the total pay in 2022.
Rankings
In 2022, Daniel E. Geffken's compensation ranked 5,461st out of 5,542 executives tracked by ExecPay. In other words, Geffken earned more than 1.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,461 out of 5,542 | 2nd |
Division Manufacturing | 2,964 out of 3,000 | 1st |
Major group Chemicals And Allied Products | 1,342 out of 1,350 | 1st |
Industry group Drugs | 1,246 out of 1,253 | 1st |
Industry Biological Products, Except Diagnostic Substances | 286 out of 287 | 0th |
Source: SEC filing on April 28, 2023.
Geffken's colleagues
We found two more compensation records of executives who worked with Daniel E. Geffken at Sevion Therapeutics in 2022.